Agenus (AGEN) : Traders are bullish on Agenus (AGEN) as it has outperformed the S&P 500 by a wide margin of 17.57% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 3.89%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 4.06% in the last 1 week, and is up 16.94% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 7.95% and the 50-Day Moving Average is 17.17%.The 200 Day SMA reached 62.32%
Agenus (NASDAQ:AGEN): After opening at $7.02, the stock dipped to an intraday low of $7 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $7.2 and the buying power remained strong till the end. The stock closed at $7.18 for the day, a gain of 4.51% for the day session. The total traded volume was 1,427,232. The stocks close on the previous trading day was $7.18.
Agenus (AGEN) : 3 investment research analysts covering Agenus (AGEN) have an average price target of $8 for the near short term. The highest target price given by the Brokerage Firm to the stock is $10 and the lowest target is $7 for the short term. Analysts expect the variance to be within $1.73 of the average price.
Agenus Inc. (Agenus) is an immunotherapy company. The Company is engaged in discovering and developing treatments for patients with cancer and other diseases. Its approaches are driven by three platform technologies: Its antibody platform, including Retrocyte Display technology, which is designed to produce human monoclonal antibodies focused on advancing checkpoint modulators (CPMs); its heat shock protein (HSP)-based vaccines, and its saponin-based vaccine adjuvants, QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company has a portfolio of programs in pre-clinical and clinical stages, including a series of CPMs in investigational new drug (IND)-enabling studies, Prophage Series vaccine, a Phase III ready HSP-based autologous vaccine for glioblastoma multiforme (GBM), which is a form of brain cancer, and a number of QS-21 Stimulon-containing vaccine candidates in late stage development by its partner, GlaxoSmithKline (GSK).